Endometrial Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: END041 MIFTS: 60	Endometrial Adenocarcinoma Categories: Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Endometrial Adenocarcinoma

MalaCards integrated aliases for Endometrial Adenocarcinoma:

Name: Endometrial Adenocarcinoma ¹² ¹⁵ ⁷⁴

Endometrial Endometrioid Adenocarcinoma ¹² ¹⁷ ⁷⁴

Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation ⁶ ¹⁷

Endometrial Adenoacanthoma ¹² ⁷⁴

Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation ¹²

Endometrioid Carcinoma of Endometrium ¹²

Endometrioid Adenomas and Carcinomas ¹²

Adenocarcinoma of the Endometrium ¹²

Endometrioid Adenoma or Carcinoma ¹²

Adenocarcinoma of Endometrium ¹²

Endometrium Adenocarcinoma ¹⁷

Adenocarcinoma of Uterus ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:2870

NCIt ⁵¹ C6287 C6290 C7359

EFO ¹⁷ EFO_0005232 EFO_1000233 EFO_1001953

UMLS ⁷⁴ C0279763 C1153706 C1336905

Sources

Summaries for Endometrial Adenocarcinoma

Disease Ontology : ¹² An endometrial carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Endometrial Adenocarcinoma, also known as endometrial endometrioid adenocarcinoma, is related to endometrial clear cell adenocarcinoma and endometrial mucinous adenocarcinoma. An important gene associated with Endometrial Adenocarcinoma is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Dexmedetomidine and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and breast, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Sources

Related Diseases for Endometrial Adenocarcinoma

Diseases related to Endometrial Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 312)

#	Related Disease	Score	Top Affiliating Genes
1	endometrial clear cell adenocarcinoma	32.6	CTSD ESR1
2	endometrial mucinous adenocarcinoma	32.3	CDKN2A ESR1 MKI67 PGR
3	adenomyosis	31.2	ESR1 PGR VEGFA
4	mucinous adenocarcinoma	31.1	CDKN2A KRAS KRT7 MLH1
5	papillary serous adenocarcinoma	30.8	KRT7 PGR TP53
6	adenocarcinoma	30.8	AKT1 CDKN2A ERBB2 FGFR2 KRAS MALAT1
7	adenocarcinoma in situ	30.7	CDKN2A KRAS KRT7
8	endometriosis	30.6	ESR1 ESR2 PGR PTEN VEGFA
9	cervical squamous cell carcinoma	30.5	CDKN2A MKI67 TP53
10	carcinosarcoma	30.4	ERBB2 KRAS KRT7 PGR PTEN TP53
11	adenosarcoma	30.3	ESR1 MKI67 PGR TP53
12	papilloma	30.2	CDKN2A KRT7 PTEN TP53
13	papillary adenocarcinoma	30.2	ERBB2 KRT7 PGR TP53
14	leiomyoma	30.1	ESR1 ESR2 MKI67 PGR
15	endometriosis of ovary	30.0	ESR1 ESR2 PGR
16	wilms tumor 1	29.9	ERBB2 ESR1 KRT7 PGR TP53
17	gastrointestinal stromal tumor	29.8	AKT1 CDKN2A KRAS MKI67 PTEN TP53
18	ovarian disease	29.7	AKT1 ESR1 ESR2 PGR PTEN TP53
19	hemangioma	29.6	FGF2 KRAS PTEN VEGFA
20	endometrial stromal sarcoma	29.6	ESR1 MALAT1 PGR TP53
21	squamous cell carcinoma	29.0	AKT1 CDKN2A ERBB2 FGFR2 MALAT1 MKI67
22	lung cancer susceptibility 3	28.7	AKT1 CDKN2A ERBB2 ESR2 KRAS KRT7
23	endometrial cancer	28.6	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
24	colorectal cancer	28.1	AKT1 CDKN2A CTSD ERBB2 ESR2 KRAS
25	breast cancer	27.5	AKT1 CTSD ERBB2 ESR1 ESR2 FGF2
26	villoglandular endometrial endometrioid adenocarcinoma	11.2
27	oxyphilic endometrial endometrioid adenocarcinoma	11.2
28	secretory uterine corpus endometrioid adenocarcinoma	11.2
29	mucin-rich endometrial endometrioid adenocarcinoma	11.2
30	sarcomatoid uterine corpus endometrioid adenocarcinoma	11.2
31	endometrial mixed adenocarcinoma	11.2
32	vestibular gland benign neoplasm	10.6	ESR1 PGR
33	vulvar benign neoplasm	10.6	ESR1 PGR
34	trigonitis	10.6	ESR1 PGR
35	vulvar syringoma	10.6	ESR1 PGR
36	lung leiomyoma	10.6	ESR1 PGR
37	vulvar leiomyoma	10.6	ESR1 PGR
38	bartholin's gland adenoma	10.6	ESR1 PGR
39	vulvar dystrophy	10.6	CDKN2A PGR
40	predominantly cortical thymoma	10.6	ESR1 PGR
41	breast duct papilloma	10.6	PGR PTEN
42	endometrium carcinoma in situ	10.6	PGR TP53
43	bizarre leiomyoma	10.6	CDKN2A PGR
44	bladder squamous cell carcinoma	10.6	CDKN2A TP53
45	infiltrating angiolipoma	10.6	CDKN2A VEGFA
46	mucinous stomach adenocarcinoma	10.6	PTEN VEGFA
47	endosalpingiosis	10.6	KRT7 PGR
48	mucinous adenofibroma	10.6	ESR1 KRT7
49	hyperplastic polyposis syndrome	10.6	KRAS TP53
50	eccrine papillary adenocarcinoma	10.6	KRT7 PGR

Graphical network of the top 20 diseases related to Endometrial Adenocarcinoma:

Sources

Symptoms & Phenotypes for Endometrial Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.35	CTSD ERBB2 FGFR2 PTEN VEGFA
2	Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)	GR00104-A-0	8.92	ESR1 ESR2 MKI67 PTEN

MGI Mouse Phenotypes related to Endometrial Adenocarcinoma:

⁴⁷ (show all 27)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.5	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
2	cellular	MP:0005384	10.49	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
3	behavior/neurological	MP:0005386	10.47	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
4	cardiovascular system	MP:0005385	10.44	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
5	endocrine/exocrine gland	MP:0005379	10.41	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
6	growth/size/body region	MP:0005378	10.4	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
7	hematopoietic system	MP:0005397	10.39	AKT1 CDKN2A CTSD ESR1 ESR2 FGF2
8	immune system	MP:0005387	10.37	AKT1 CDKN2A CTSD ESR1 ESR2 FGFR2
9	integument	MP:0010771	10.36	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
10	mortality/aging	MP:0010768	10.36	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
11	digestive/alimentary	MP:0005381	10.35	CDKN2A CTSD ERBB2 ESR1 ESR2 FGFR2
12	embryo	MP:0005380	10.3	AKT1 CDKN2A ERBB2 ESR1 FGFR2 KRAS
13	neoplasm	MP:0002006	10.29	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
14	muscle	MP:0005369	10.27	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
15	nervous system	MP:0003631	10.23	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2
16	limbs/digits/tail	MP:0005371	10.19	ERBB2 ESR1 ESR2 FGFR2 KRAS PGR
17	adipose tissue	MP:0005375	10.18	AKT1 ESR1 ESR2 FGFR2 LNPEP PTEN
18	liver/biliary system	MP:0005370	10.18	AKT1 CDKN2A ESR1 ESR2 FGFR2 KRAS
19	normal	MP:0002873	10.14	AKT1 ERBB2 ESR1 ESR2 FGFR2 KRAS
20	no phenotypic analysis	MP:0003012	10.13	CDKN2A ESR1 ESR2 FGFR2 KRAS LNPEP
21	reproductive system	MP:0005389	10.07	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
22	hearing/vestibular/ear	MP:0005377	10.06	CTSD ESR2 FGF2 FGFR2 KRAS TP53
23	renal/urinary system	MP:0005367	9.92	ESR1 ESR2 FGFR2 KRAS KRT7 PTEN
24	respiratory system	MP:0005388	9.9	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGFR2
25	pigmentation	MP:0001186	9.77	CDKN2A FGFR2 KRAS PTEN TP53
26	skeleton	MP:0005390	9.73	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
27	vision/eye	MP:0005391	9.28	CDKN2A CTSD FGF2 FGFR2 KRAS MLH1

Sources

Drugs & Therapeutics for Endometrial Adenocarcinoma

Drugs for Endometrial Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dexmedetomidine

Approved, Vet_approved

Phase 4

113775-47-6

68602 5311068

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1

3821

Central Nervous System Depressants

Phase 4

Peripheral Nervous System Agents

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic alpha-2 Receptor Agonists

Phase 4

Neurotransmitter Agents

Phase 4

Anesthetics

Phase 4

Anesthetics, Dissociative

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, Local

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agents

Phase 4

Analgesics

Phase 4

Anesthetics, General

Phase 4

Analgesics, Non-Narcotic

Phase 4

Excitatory Amino Acids

Phase 4

Hypnotics and Sedatives

Phase 4

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Carboplatin

Approved

Phase 2, Phase 3,Phase 1

41575-94-4

38904 10339178 498142

Doxorubicin

Approved, Investigational

Phase 3,Phase 1

23214-92-8

31703

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

441203 84093 2767

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Epirubicin

Approved

Phase 3

56420-45-2

41867

Metformin

Approved

Phase 2, Phase 3,Early Phase 1,Not Applicable

657-24-9

14219 4091

Doxil

Approved June 1999

Phase 3,Phase 1

31703

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Hormones

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Adjuvants, Immunologic

Phase 3

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Hypoglycemic Agents

Phase 2, Phase 3,Early Phase 1,Not Applicable

Estrogens

Phase 3,Phase 2,Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 2,Phase 1

Hormone Antagonists

Phase 3,Phase 2,Phase 1

Estrogens, Conjugated (USP)

Phase 3

Medroxyprogesterone acetate

Approved, Investigational

Phase 2

71-58-9

Levonorgestrel

Approved, Investigational

Phase 2,Not Applicable

17489-40-6, 797-63-7

13109

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 2

595-33-5

11683

Docetaxel

Approved, Investigational

Phase 2,Phase 1

114977-28-5

148124

Amifostine

Approved, Investigational

Phase 2

20537-88-6

2141

Gemcitabine

Approved

Phase 2,Phase 1

95058-81-4

60750

Everolimus

Approved

Phase 2,Phase 1

159351-69-6

6442177 70789204

Sirolimus

Approved, Investigational

Phase 2,Phase 1

53123-88-9

46835353 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 87)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines	Completed	NCT03164590	Phase 4	Ketamine;dexmedetomidine;bupivacaine
2	Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus	Completed	NCT00002706	Phase 3
3	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4	Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer	Completed	NCT00005583	Phase 3	cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5	Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery	Completed	NCT00002807	Phase 3
6	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer	Completed	NCT00002493	Phase 3	cisplatin;doxorubicin hydrochloride
7	Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer	Completed	NCT00006027	Phase 3	cisplatin;paclitaxel
8	Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer	Recruiting	NCT03422198	Phase 3
9	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
10	Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer	Active, not recruiting	NCT01672892	Phase 3
11	Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer	Terminated	NCT00002976	Phase 3	conjugated estrogens
12	The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy	Unknown status	NCT02335203	Phase 2	Depot medroxyprogesterone acetate
13	Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer	Unknown status	NCT01594879	Phase 2
14	Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer	Unknown status	NCT01041027	Phase 2	Paclitaxel;Carboplatin
15	Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma	Completed	NCT01968317	Phase 2	Megestrol acetate and metformin;Megestrol acetate
16	A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women	Completed	NCT01877564	Phase 2	Metformin
17	A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation	Completed	NCT00285415	Phase 2	Docetaxel and Carboplatin
18	S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer	Completed	NCT00003127	Phase 2	amifostine trihydrate;carboplatin;paclitaxel
19	Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus	Completed	NCT00064025	Phase 2	Medroxyprogesterone
20	Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00095979	Phase 2	ixabepilone
21	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01011933	Phase 2	Selumetinib
22	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
23	Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer	Completed	NCT00870337	Phase 2	everolimus
24	Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	Completed	NCT00006089	Phase 2
25	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
26	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01132820	Phase 2	Cediranib Maleate
27	Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer	Completed	NCT00087100	Phase 2	pemetrexed disodium
28	Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer	Completed	NCT00004251	Phase 2	letrozole
29	Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer	Completed	NCT00030485	Phase 2	erlotinib hydrochloride
30	Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00025467	Phase 2	thalidomide
31	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01642082	Phase 2
32	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01225887	Phase 2	Nintedanib
33	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer	Completed	NCT01210222	Phase 2
34	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
35	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00888173	Phase 2	Brivanib Alaninate
36	Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
37	Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer	Completed	NCT00770185	Phase 2	ridaforolimus
38	Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery	Completed	NCT00331760	Phase 2	cisplatin
39	Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.	Recruiting	NCT03540407	Phase 2
40	Pembro/Carbo/Taxol in Endometrial Cancer	Recruiting	NCT02549209	Phase 2	Pembrolizumab;Paclitaxel;Carboplatin
41	Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer	Recruiting	NCT03643510	Phase 2	Fulvestrant;Abemaciclib
42	Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)	Recruiting	NCT02730923	Phase 1, Phase 2	AZD2014;Anastrozole
43	Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer	Recruiting	NCT02730429	Phase 2	Palbociclib/placebo;Letrozole
44	Improving the Treatment for Women With Early Stage Cancer of the Uterus	Recruiting	NCT01686126	Phase 2	Levonorgestrel;Metformin
45	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer	Recruiting	NCT00492778	Phase 2	Cisplatin
46	An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors	Recruiting	NCT02697591	Phase 1, Phase 2	INCAGN01876
47	Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06	Recruiting	NCT01164150	Phase 2
48	Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer	Recruiting	NCT03300557	Phase 2	Exemestane
49	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	Active, not recruiting	NCT00977574	Phase 2	Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
50	Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer	Active, not recruiting	NCT00478426	Phase 2	Sunitinib Malate

Search NIH Clinical Center for Endometrial Adenocarcinoma

Sources

Genetic Tests for Endometrial Adenocarcinoma

Sources

Anatomical Context for Endometrial Adenocarcinoma

MalaCards organs/tissues related to Endometrial Adenocarcinoma:

⁴²

Uterus, Lymph Node, Breast, Endothelial, Ovary, Cervix, Liver

Sources

Publications for Endometrial Adenocarcinoma

Articles related to Endometrial Adenocarcinoma:

(show top 50) (show all 1078)

#	Title	Authors	Year
1	Gprotein-coupled estrogen receptor 30 and extracellular signal-regulated kinase 1/2 in endometrial adenocarcinoma. ( 30915827 )	Li YM...Yang HL	2019
2	Peri-Ampullary Metastasis From Endometrial Adenocarcinoma: A Rare Etiology of Obstructive Jaundice. ( 30834033 )	Ahmmad E...Dirweesh A	2019
3	A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. ( 30770127 )	Alimena S...Horowitz N	2019
4	Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression. ( 30789355 )	Huang HN...Kuo KT	2019
5	RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma. ( 30684972 )	Liu S...Meng F	2019
6	Expression and role of hScrib in endometrium, endometriosis, and endometrial adenocarcinoma. ( 30702562 )	Ouyang Z...Zhai J	2019
7	L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB. ( 30591489 )	Klat J...Simetka O	2019
8	Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma. ( 29210800 )	Gan Q...Broaddus RR	2019
9	Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution. ( 29683879 )	Kumar U.P....Mamidipudi V.S.	2018
10	Endometrial Adenocarcinoma With Pulmonary Recurrence. ( 29326341 )	Rai M.P....Marinas E.B.	2018
11	Endometrial Adenocarcinoma, Endometrioid Type. ( 29976383 )	Erickson L.A.	2018
12	Synchronous endometrial adenocarcinoma and carcinosarcoma in endometrial polyp. ( 29854405 )	Alnimer Y....Azher Q.	2018
13	LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle. ( 29358688 )	Suh D.S....Bae J.	2018
14	Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma. ( 29891190 )	Mhawech-Fauceglia P....Lawrenson K.	2018
15	Amide Proton Transfer MR Imaging of Endometrioid Endometrial Adenocarcinoma: Association with Histologic Grade. ( 29083987 )	Takayama Y....Honda H.	2018
16	Pathological and molecular diagnosis of bilateral inguinal lymph nodes metastases from low-grade endometrial adenocarcinoma: a case report with review of the literature. ( 29295713 )	Perrone A.M....De Iaco P.	2018
17	Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. ( 29266019 )	Fan Z....Gu L.	2018
18	Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing. ( 29937308 )	Choi Y.J....Lee S.H.	2018
19	Remarkable response of recurrent endometrial adenocarcinoma to daily oral administration of half-dose etoposide. ( 30788108 )	Nakamura Y...Miwa I	2018
20	Isolated Gastric Metastasis of Endometrial Adenocarcinoma: First Case Report and Review of Pertinent Literature. ( 30627266 )	Cui M...Harpaz N	2018
21	BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway. ( 30445932 )	Wang F...Li B	2018
22	The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. ( 30479097 )	Guan J...Chen X	2018
23	Diagnostic Value of Assessment of Cervical Involvement in Early-Stage Endometrial Adenocarcinoma: Comparison of Magnetic Resonance Imaging (MRI) Versus Hysteroscopy. ( 30398217 )	Xu G...Zhang B	2018
24	The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes. ( 30425513 )	Devor EJ...Leslie KK	2018
25	The cigarette smoke components induced the cell proliferation and epithelial to mesenchymal transition via production of reactive oxygen species in endometrial adenocarcinoma cells. ( 30236600 )	Kim SM...Choi KC	2018
26	Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma ( 30139240 )	Assaf MI...Mohamed EA	2018
27	Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease. ( 29898896 )	Mukherjee A...Teixeira JM	2018
28	Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. ( 28836043 )	Agopiantz M....Gauchotte G.	2017
29	Ichthyosis Uteri Associated with Endometrial Adenocarcinoma: A Case Report. ( 28764184 )	Bhardwaj N....Mishra K.	2017
30	Gastric-Type Endometrial Adenocarcinoma: Report of Two Cases in Patients From the United States. ( 29281925 )	McCarthy W.A....Quddus M.R.	2017
31	Endometrial adenocarcinoma recurrence presenting with tibial metastasis: Report of a case. ( 28500904 )	SAPylemez M.S....Ozkan K.	2017
32	Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma. ( 28958736 )	Jordan S.E....Micaily B.	2017
33	Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma. ( 28831417 )	Newtson A.M....Westin S.N.	2017
34	Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations. ( 28819700 )	Buecher B....Golmard L.	2017
35	Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma. ( 29243125 )	Hotton J....Gauchotte G.	2017
36	Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair. ( 29084048 )	Lee P.J....Hagemann I.S.	2017
37	Sentinel lymph node mapping reduces practice pattern variations in surgical staging for endometrial adenocarcinoma: A before and after study. ( 28363672 )	Liu C.Y....Feltmate C.M.	2017
38	MiR-106a promotes tumor growth, migration, and invasion by targeting<i>BCL2L11</i>in human endometrial adenocarcinoma. ( 29218096 )	Tang W....Liu M.	2017
39	Endometrial adenocarcinoma with choriocarcinomatous differentiation in the uterus of a goat. ( 28529267 )	Kawashima M....Shibutani M.	2017
40	Deep Infiltrating Endometriosis and Endometrial Adenocarcinoma Express High Levels of Myostatin and Its Receptors Messenger RNAs. ( 28345488 )	Carrarelli P....Petraglia F.	2017
41	Robotic Splenectomy for Isolated Splenic Recurrence of Endometrial Adenocarcinoma. ( 29128439 )	Gallotta V....Scambia G.	2017
42	Endometrioid endometrial adenocarcinoma: an increase of G3 cancers? ( 28421274 )	Mang C....Humburg J.	2017
43	Hypermethylation of WIF1 and its inhibitory role in the tumor growth of endometrial adenocarcinoma. ( 28944908 )	Deng X....Zhu L.	2017
44	Corrigendum to &quot;Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells&quot; [J Nutr Biochem 44 (2017) 60-70]. ( 29078859 )	Sirohi V.K....Dwivedi A.	2017
45	Difference in Diffusion-Weighted Magnetic Resonance Imaging and Diffusion Tensor Imaging Parameters Between Endometrioid Endometrial Adenocarcinoma and Uterine Serous Adenocarcinoma: A Retrospective Study. ( 28945213 )	Tian S....Wei Q.	2017
46	Impact of laparoscopy on the biological behavior and gene expression of endometrial adenocarcinoma cells. ( 28656791 )	Huang S....Wang H.	2017
47	Pap Smears in Endometrial Adenocarcinoma: Does It Have a Role? ( 28547956 )	Nadaf A....Shastri D.	2017
48	The importance of hCG in human endometrial adenocarcinoma and breast cancer. ( 28967068 )	KAPlbl A.C....Andergassen U.	2017
49	Radiation-induced circumscribed superficial morphea after brachytherapy for endometrial adenocarcinoma. ( 29234720 )	Trivedi A....McGevna L.	2017
50	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. ( 28969912 )	Devor E.J....Leslie K.K.	2017

Sources

Genes for Endometrial Adenocarcinoma

Genes related to Endometrial Adenocarcinoma (2 elite genes):

(show all 28)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	420.64	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	409.74	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	25085246
4	MIR204	MicroRNA 204	RNA Gene	50	Unspecified ⁴⁸	19077565
5	PGR	Progesterone Receptor	Protein Coding	24.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	ESR1	Estrogen Receptor 1	Protein Coding	24.27	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	TP53	Tumor Protein P53	Protein Coding	23.47	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	PTEN	Phosphatase And Tensin Homolog	Protein Coding	22.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	22.03	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	ESR2	Estrogen Receptor 2	Protein Coding	21.73	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	KRT7	Keratin 7	Protein Coding	21.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	MKI67	Marker Of Proliferation Ki-67	Protein Coding	21.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	MLH1	MutL Homolog 1	Protein Coding	21.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	21.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	FGF2	Fibroblast Growth Factor 2	Protein Coding	21.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	CTSD	Cathepsin D	Protein Coding	21.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	21.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	LNPEP	Leucyl And Cystinyl Aminopeptidase	Protein Coding	21	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	THEMIS2	Thymocyte Selection Associated Family Member 2	Protein Coding	20.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Expressions (show sections)
21	EGFR	Epidermal Growth Factor Receptor	Protein Coding	20.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CTNNB1	Catenin Beta 1	Protein Coding	20.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	PAEP	Progestagen Associated Endometrial Protein	Protein Coding	11.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	PTGFR	Prostaglandin F Receptor	Protein Coding	10.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	10.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
26	EMP2	Epithelial Membrane Protein 2	Protein Coding	10.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
27	HOXA10	Homeobox A10	Protein Coding	10.45	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
28	CCND1	Cyclin D1	Protein Coding	10.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Endometrial Adenocarcinoma

ClinVar genetic disease variations for Endometrial Adenocarcinoma:

⁶ (show all 36)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	FGFR2	NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp)	single nucleotide variant	Pathogenic	rs79184941	GRCh37	Chromosome 10, 123279677: 123279677
2	FGFR2	NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp)	single nucleotide variant	Pathogenic	rs79184941	GRCh38	Chromosome 10, 121520163: 121520163
3	AKT1	NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434592	GRCh37	Chromosome 14, 105246551: 105246551
4	AKT1	NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434592	GRCh38	Chromosome 14, 104780214: 104780214
5	FGFR2	NM_000141.4(FGFR2): c.1694A> G (p.Glu565Gly)	single nucleotide variant	Likely pathogenic	rs121918506	GRCh37	Chromosome 10, 123256215: 123256215
6	FGFR2	NM_000141.4(FGFR2): c.1694A> G (p.Glu565Gly)	single nucleotide variant	Likely pathogenic	rs121918506	GRCh38	Chromosome 10, 121496701: 121496701
7	FGFR2	NM_000141.4(FGFR2): c.1645A> C (p.Asn549His)	single nucleotide variant	Likely pathogenic	rs1057519045	GRCh37	Chromosome 10, 123258036: 123258036
8	FGFR2	NM_000141.4(FGFR2): c.1645A> C (p.Asn549His)	single nucleotide variant	Likely pathogenic	rs1057519045	GRCh38	Chromosome 10, 121498522: 121498522
9	EGFR	NM_005228.4(EGFR): c.2068G> A (p.Glu690Lys)	single nucleotide variant	Likely pathogenic	rs1057519794	GRCh37	Chromosome 7, 55241620: 55241620
10	EGFR	NM_005228.4(EGFR): c.2068G> A (p.Glu690Lys)	single nucleotide variant	Likely pathogenic	rs1057519794	GRCh38	Chromosome 7, 55173927: 55173927
11	FGFR2	NM_022970.3(FGFR2): c.1978A> G (p.Lys660Glu)	single nucleotide variant	Likely pathogenic	rs1057519795	GRCh37	Chromosome 10, 123247516: 123247516
12	FGFR2	NM_022970.3(FGFR2): c.1978A> G (p.Lys660Glu)	single nucleotide variant	Likely pathogenic	rs1057519795	GRCh38	Chromosome 10, 121488002: 121488002
13	FGFR2	NM_000141.4(FGFR2): c.1849T> A (p.Leu617Met)	single nucleotide variant	Likely pathogenic	rs1057519796	GRCh37	Chromosome 10, 123256060: 123256060
14	FGFR2	NM_000141.4(FGFR2): c.1849T> A (p.Leu617Met)	single nucleotide variant	Likely pathogenic	rs1057519796	GRCh38	Chromosome 10, 121496546: 121496546
15	FGFR2	NM_000141.4(FGFR2): c.1690G> A (p.Val564Ile)	single nucleotide variant	Likely pathogenic	rs1057519797	GRCh37	Chromosome 10, 123256219: 123256219
16	FGFR2	NM_000141.4(FGFR2): c.1690G> A (p.Val564Ile)	single nucleotide variant	Likely pathogenic	rs1057519797	GRCh38	Chromosome 10, 121496705: 121496705
17	FGFR2	NM_022970.3(FGFR2): c.1650T> G (p.Asn550Lys)	single nucleotide variant	Likely pathogenic	rs121913476	GRCh37	Chromosome 10, 123258034: 123258034
18	FGFR2	NM_022970.3(FGFR2): c.1650T> G (p.Asn550Lys)	single nucleotide variant	Likely pathogenic	rs121913476	GRCh38	Chromosome 10, 121498520: 121498520
19	FGFR2	NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys)	single nucleotide variant	Likely pathogenic	rs121913476	GRCh37	Chromosome 10, 123258034: 123258034
20	FGFR2	NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys)	single nucleotide variant	Likely pathogenic	rs121913476	GRCh38	Chromosome 10, 121498520: 121498520
21	FGFR2	NM_000141.4(FGFR2): c.1639A> G (p.Ile547Val)	single nucleotide variant	Likely pathogenic	rs1057519798	GRCh37	Chromosome 10, 123258042: 123258042
22	FGFR2	NM_000141.4(FGFR2): c.1639A> G (p.Ile547Val)	single nucleotide variant	Likely pathogenic	rs1057519798	GRCh38	Chromosome 10, 121498528: 121498528
23	FGFR2	NM_022970.3(FGFR2): c.1614G> T (p.Met538Ile)	single nucleotide variant	Likely pathogenic	rs1057519799	GRCh37	Chromosome 10, 123258070: 123258070
24	FGFR2	NM_022970.3(FGFR2): c.1614G> T (p.Met538Ile)	single nucleotide variant	Likely pathogenic	rs1057519799	GRCh38	Chromosome 10, 121498556: 121498556
25	FGFR2	NM_022970.3(FGFR2): c.1614G> C (p.Met538Ile)	single nucleotide variant	Likely pathogenic	rs1057519799	GRCh37	Chromosome 10, 123258070: 123258070
26	FGFR2	NM_022970.3(FGFR2): c.1614G> C (p.Met538Ile)	single nucleotide variant	Likely pathogenic	rs1057519799	GRCh38	Chromosome 10, 121498556: 121498556
27	FGFR2	NM_000141.4(FGFR2): c.1611G> A (p.Met537Ile)	single nucleotide variant	Likely pathogenic	rs1057519799	GRCh37	Chromosome 10, 123258070: 123258070
28	FGFR2	NM_000141.4(FGFR2): c.1611G> A (p.Met537Ile)	single nucleotide variant	Likely pathogenic	rs1057519799	GRCh38	Chromosome 10, 121498556: 121498556
29	FGFR2	NM_000141.4(FGFR2): c.1605G> T (p.Met535Ile)	single nucleotide variant	Likely pathogenic	rs1057519800	GRCh37	Chromosome 10, 123258076: 123258076
30	FGFR2	NM_000141.4(FGFR2): c.1605G> T (p.Met535Ile)	single nucleotide variant	Likely pathogenic	rs1057519800	GRCh38	Chromosome 10, 121498562: 121498562
31	FGFR2	NM_022970.3(FGFR2): c.1608G> C (p.Met536Ile)	single nucleotide variant	Likely pathogenic	rs1057519800	GRCh37	Chromosome 10, 123258076: 123258076
32	FGFR2	NM_022970.3(FGFR2): c.1608G> C (p.Met536Ile)	single nucleotide variant	Likely pathogenic	rs1057519800	GRCh38	Chromosome 10, 121498562: 121498562
33	FGFR2	NM_022970.3(FGFR2): c.1608G> A (p.Met536Ile)	single nucleotide variant	Likely pathogenic	rs1057519800	GRCh37	Chromosome 10, 123258076: 123258076
34	FGFR2	NM_022970.3(FGFR2): c.1608G> A (p.Met536Ile)	single nucleotide variant	Likely pathogenic	rs1057519800	GRCh38	Chromosome 10, 121498562: 121498562
35	PIK3R2	NM_005027.3(PIK3R2): c.1681A> G (p.Asn561Asp)	single nucleotide variant	Likely pathogenic	rs1057519801	GRCh37	Chromosome 19, 18278061: 18278061
36	PIK3R2	NM_005027.3(PIK3R2): c.1681A> G (p.Asn561Asp)	single nucleotide variant	Likely pathogenic	rs1057519801	GRCh38	Chromosome 19, 18167251: 18167251

Cosmic variations for Endometrial Adenocarcinoma:

⁹ (show top 50) (show all 4244)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM6935601	ZRSR2	endometrium,NS,carcinoma,endometrioid carcinoma	c.1124G>T	p.S375I	23:15822917-15822917
2	COSM6982868	ZRSR2	endometrium,NS,carcinoma,endometrioid carcinoma	c.854C>A	p.S285Y	23:15820233-15820233
3	COSM6935600	ZRSR2	endometrium,NS,carcinoma,endometrioid carcinoma	c.514T>A	p.C172S	23:15809275-15809275
4	COSM6845183	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.2143C>T	p.R715*	16:72958003-72958003
5	COSM6845177	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.7490C>T	p.S2497L	16:72795192-72795192
6	COSM6978508	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.9856G>A	p.A3286T	16:72788420-72788420
7	COSM6845125	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.2770T>G	p.S924A	16:72950915-72950915
8	COSM6845174	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.4129C>A	p.L1377I	16:72798553-72798553
9	COSM6845142	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.3504G>T	p.E1168D	16:72829804-72829804
10	COSM6845190	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.9555A>C	p.Q3185H	16:72788721-72788721
11	COSM6845164	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.7666G>C	p.A2556P	16:72795016-72795016
12	COSM6845182	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.3628C>T	p.R1210*	16:72811940-72811940
13	COSM6845133	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.2740G>A	p.D914N	16:72950945-72950945
14	COSM6845156	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.2875G>A	p.D959N	16:72950810-72950810
15	COSM6845152	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.1109G>A	p.G370D	16:72959037-72959037
16	COSM6845162	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.6473G>A	p.R2158Q	16:72796209-72796209
17	COSM973493	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.9001G>T	p.E3001*	16:72793681-72793681
18	COSM6826430	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.8002C>T	p.R2668*	16:72794680-72794680
19	COSM6845155	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.2725G>A	p.G909S	16:72950960-72950960
20	COSM1233352	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.6446G>A	p.R2149H	16:72796236-72796236
21	COSM6826396	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.568G>A	p.V190M	16:72959578-72959578
22	COSM6845159	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.3829G>A	p.V1277M	16:72811612-72811612
23	COSM5563443	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.6820C>T	p.Q2274*	16:72795862-72795862
24	COSM6845186	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.9266A>C	p.E3089A	16:72793416-72793416
25	COSM6984593	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.6046G>A	p.E2016K	16:72796636-72796636
26	COSM973492	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.9006G>T	p.K3002N	16:72793676-72793676
27	COSM6984595	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.5623G>A	p.E1875K	16:72797059-72797059
28	COSM6845173	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.3863C>T	p.T1288M	16:72811578-72811578
29	COSM6845141	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.1969G>A	p.G657S	16:72958177-72958177
30	COSM6982810	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.4103A>G	p.N1368S	16:72798579-72798579
31	COSM6845171	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.3115C>T	p.H1039Y	16:72950570-72950570
32	COSM973535	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.4316G>A	p.R1439Q	16:72798366-72798366
33	COSM1640552	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.8849G>A	p.R2950H	16:72793833-72793833
34	COSM6982809	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.4406C>T	p.A1469V	16:72798276-72798276
35	COSM6984596	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.1378G>A	p.E460K	16:72958768-72958768
36	COSM6845169	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.5125G>T	p.E1709*	16:72797557-72797557
37	COSM6845189	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.8228A>G	p.Y2743C	16:72794454-72794454
38	COSM3276999	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.359G>A	p.G120E	16:72959787-72959787
39	COSM3276890	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.3397G>A	p.E1133K	16:72889782-72889782
40	COSM1379731	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.884G>A	p.R295H	16:72959262-72959262
41	COSM6845185	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.5635A>T	p.K1879*	16:72797047-72797047
42	COSM6845129	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.7559T>C	p.L2520P	16:72795123-72795123
43	COSM6845179	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.8576C>T	p.T2859M	16:72794106-72794106
44	COSM973560	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.1115G>A	p.R372Q	16:72959031-72959031
45	COSM6845178	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.8197C>A	p.R2733S	16:72794485-72794485
46	COSM6845161	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.5754G>T	p.K1918N	16:72796928-72796928
47	COSM6845188	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.6058A>G	p.K2020E	16:72796624-72796624
48	COSM6984594	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.5941G>A	p.E1981K	16:72796741-72796741
49	COSM6845165	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.8078G>A	p.R2693Q	16:72794604-72794604
50	COSM6845127	ZFHX3	endometrium,NS,carcinoma,endometrioid carcinoma	c.4274T>C	p.I1425T	16:72798408-72798408

Sources

Expression for Endometrial Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Adenocarcinoma.

Sources

Pathways for Endometrial Adenocarcinoma

Pathways related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	13.9	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
2	Gene Expression ⁶⁷ Show member pathways Generic Transcription Pathway ⁶⁷	13.86	AKT1 CDKN2A ERBB2 ESR1 ESR2 MLH1
3	GPCR Pathway ⁶⁵ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁵ Estrogen Pathway ⁶⁵ NFAT in Immune Response ⁶⁵ P2Y Receptor Signaling ⁶⁵ Pancreatic Adenocarcinoma ⁶⁵ Paxillin Interactions ⁶⁵ Ras Pathway ⁶⁵	13.77	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
4	Class I MHC mediated antigen processing and presentation ⁶⁷ Show member pathways Adaptive Immune System ⁶⁷ Antigen processing- Ubiquitination and Proteasome degradation ⁶⁷	13.47	AKT1 CTSD ERBB2 FGF2 FGFR2 KRAS
5	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.4	AKT1 ERBB2 FGF2 FGFR2 KRAS TP53
6	Nanog in Mammalian ESC Pluripotency ⁶⁵ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁵ eNOS Signaling ⁶⁵ GSK3 Signaling ⁶⁵	13.31	AKT1 ERBB2 ESR1 ESR2 FGF2 FGFR2
7	Phospholipase-C Pathway ⁶⁵ Show member pathways PTEN Pathway ⁶⁵	13.11	AKT1 FGF2 FGFR2 KRAS PTEN TP53
8	Circadian entrainment ³⁸ Show member pathways Cholinergic synapse ³⁸ Dopaminergic synapse ³⁸ Estrogen signaling pathway ³⁸ Glutamatergic synapse ³⁸ Relaxin receptors ⁶⁷ Relaxin signaling pathway ³⁸ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁶	13.07	AKT1 CTSD ESR1 ESR2 KRAS PGR
9	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	13	AKT1 CDKN2A FGF2 KRAS PTEN TP53
10	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	13	AKT1 ERBB2 FGF2 FGFR2 KRAS PTEN
11	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁸ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²³ Apoptosis Signaling Pathways ⁶⁶ Death Receptor Signaling ⁶⁸	12.84	AKT1 CDKN2A CTSD KRAS TP53
12	MAPK signaling pathway ¹ ³⁸	12.81	AKT1 ERBB2 FGF2 FGFR2 KRAS TP53
13	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.77	AKT1 FGF2 FGFR2 KRAS VEGFA
14	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.77	AKT1 CDKN2A ERBB2 FGFR2 KRAS MLH1
15	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.74	AKT1 ERBB2 ESR1 KRAS PTEN TP53
16	Downstream signaling events of B Cell Receptor (BCR) ⁶⁷ Show member pathways Activation of RAS in B cells ⁶⁷ Signaling by the B Cell Receptor (BCR) ⁶⁷	12.74	AKT1 ERBB2 FGF2 FGFR2 KRAS PTEN
17	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁵ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.64	AKT1 ERBB2 FGF2 KRAS TP53
18	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.64	AKT1 ERBB2 KRAS TP53 VEGFA
19	MicroRNAs in cancer ³⁸	12.56	CDKN2A ERBB2 KRAS PTEN TP53 VEGFA
20	mTOR signaling pathway (KEGG) ⁶⁶ Show member pathways mTOR signaling pathway ³⁸	12.55	AKT1 ERBB2 FGFR2 KRAS PTEN TP53
21	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.49	AKT1 ERBB2 FGFR2 KRAS TP53
22	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.49	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
23	Pathways in cancer ³⁸	12.46	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
24	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁶	12.43	AKT1 ESR1 KRAS VEGFA
25	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.43	AKT1 CTSD ERBB2 ESR1 ESR2 KRAS
26	Human T-cell leukemia virus 1 infection ³⁸	12.39	AKT1 CDKN2A KRAS TP53
27	Development Ligand-independent activation of ESR1 and ESR2 ²³ Show member pathways Transcription CREB pathway ²³ Transcription PPAR Pathway ²³	12.36	AKT1 ERBB2 ESR1 ESR2
28	Immune response IFN alpha/beta signaling pathway ²³ Show member pathways Cytokine Network ⁶⁵ Interferon alpha/beta signaling ⁶⁷ Regulation of IFNA signaling ⁶⁷	12.32	AKT1 FGF2 FGFR2 KRAS TP53
29	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²³ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁷ Immune response Oncostatin M signaling via MAPK in human cells ²³ MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.29	AKT1 KRAS TP53 VEGFA
30	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.25	AKT1 ERBB2 FGFR2 KRAS PTEN TP53
31	EGF/EGFR Signaling Pathway ¹	12.24	AKT1 ERBB2 KRAS PTEN
32	Colorectal Cancer Metastasis ⁶⁵	12.24	AKT1 KRAS MLH1 TP53 VEGFA
33	VEGF Signaling Pathway ⁶² ⁶⁸ Show member pathways Nanoparticle-mediated activation of receptor signaling ¹ TGF-beta Signaling ⁶⁸	12.24	AKT1 FGF2 FGFR2 KRAS PTEN VEGFA
34	Cellular senescence (KEGG) ³⁸	12.22	AKT1 CDKN2A KRAS PTEN TP53
35	Development EGFR signaling via small GTPases ²³ Show member pathways Development EGFR signaling via PIP3 ²³ Development PDGF signaling via MAPK cascades ²³ PDGF Pathway ¹	12.19	AKT1 ERBB2 KRAS PTEN
36	AKT Signaling Pathway ⁶⁸	12.17	AKT1 ERBB2 FGFR2 KRAS PTEN TP53
37	Proteoglycans in cancer ³⁸	12.17	AKT1 ERBB2 ESR1 FGF2 KRAS TP53
38	Signaling pathways regulating pluripotency of stem cells ³⁸	12.15	AKT1 FGF2 FGFR2 KRAS
39	Direct p53 effectors ¹	12.12	CTSD MLH1 PTEN TP53
40	Integrated Breast Cancer Pathway ¹	12.12	AKT1 ESR1 KRAS PTEN TP53 VEGFA
41	Autophagy - animal ³⁸	12.1	AKT1 CTSD KRAS PTEN
42	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.07	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2
43	Thyroid hormone signaling pathway ³⁸	12.05	AKT1 ESR1 KRAS TP53
44	Sphingolipid signaling pathway ³⁸	12.05	AKT1 CTSD KRAS PTEN TP53
45	Interleukin-4 and 13 signaling ⁶⁷	12.03	AKT1 FGF2 TP53 VEGFA
46	Signaling by ERBB4 ⁶⁷ Show member pathways Downregulation of ERBB4 signaling ⁶⁷ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁷	12	ERBB2 ESR1 KRAS PGR
47	Glioblastoma Multiforme ⁶⁵	11.99	AKT1 CDKN2A KRAS PTEN TP53
48	DNA Damage Response (only ATM dependent) ¹	11.94	AKT1 CDKN2A ERBB2 KRAS PTEN TP53
49	TGF-beta Signaling Pathways ⁶⁶	11.93	AKT1 ESR1 ESR2 KRAS
50	Nuclear Receptor transcription pathway ⁶⁷ Show member pathways Nuclear Receptors ¹	11.88	ESR1 ESR2 PGR

Sources

GO Terms for Endometrial Adenocarcinoma

Cellular components related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	9.47	AKT1 CDKN2A ERBB2 ESR1 ESR2 FGF2

Biological processes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 38)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.97	AKT1 ESR1 PGR VEGFA
2	positive regulation of cell proliferation	GO:0008284	9.97	AKT1 FGF2 FGFR2 KRAS PTEN VEGFA
3	positive regulation of transcription by RNA polymerase II	GO:0045944	9.97	AKT1 CDKN2A ESR1 FGF2 FGFR2 PGR
4	angiogenesis	GO:0001525	9.96	FGF2 FGFR2 PTEN VEGFA
5	cell-cell signaling	GO:0007267	9.95	ESR2 FGFR2 LNPEP PGR
6	MAPK cascade	GO:0000165	9.94	ERBB2 FGF2 FGFR2 KRAS
7	positive regulation of protein phosphorylation	GO:0001934	9.91	AKT1 ERBB2 KRAS VEGFA
8	positive regulation of protein kinase B signaling	GO:0051897	9.89	ERBB2 ESR1 FGF2 FGFR2
9	cytokine-mediated signaling pathway	GO:0019221	9.85	AKT1 FGF2 KRAS TP53 VEGFA
10	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.84	FGF2 FGFR2 PTEN
11	negative regulation of apoptotic process	GO:0043066	9.83	AKT1 PTEN TP53 VEGFA
12	regulation of protein stability	GO:0031647	9.82	CDKN2A KRAS PTEN
13	positive regulation of endothelial cell proliferation	GO:0001938	9.81	AKT1 FGF2 VEGFA
14	positive regulation of epithelial cell proliferation	GO:0050679	9.8	ERBB2 FGFR2 VEGFA
15	protein catabolic process	GO:0030163	9.76	AKT1 CTSD LNPEP
16	positive regulation of blood vessel endothelial cell migration	GO:0043536	9.75	AKT1 FGF2 VEGFA
17	positive regulation of cell division	GO:0051781	9.73	FGF2 FGFR2 VEGFA
18	phosphatidylinositol phosphorylation	GO:0046854	9.73	ERBB2 ESR1 FGF2 FGFR2
19	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.71	AKT1 ESR1 ESR2 PTEN
20	positive regulation of cardiac muscle cell proliferation	GO:0060045	9.69	FGF2 FGFR2 MIR204
21	positive regulation of phospholipase C activity	GO:0010863	9.68	ESR1 FGF2
22	replicative senescence	GO:0090399	9.67	CDKN2A TP53
23	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.66	ESR1 TP53
24	negative regulation of cell size	GO:0045792	9.65	AKT1 PTEN
25	paracrine signaling	GO:0038001	9.62	FGF2 PGR
26	regulation of branching involved in prostate gland morphogenesis	GO:0060687	9.62	ESR1 FGFR2
27	prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	GO:0060527	9.61	ESR1 FGFR2
28	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.57	CDKN2A ERBB2
29	Ras protein signal transduction	GO:0007265	9.56	CDKN2A FGF2 KRAS TP53
30	cellular response to decreased oxygen levels	GO:0036294	9.54	AKT1 PTEN
31	cell migration involved in sprouting angiogenesis	GO:0002042	9.5	AKT1 FGF2 VEGFA
32	prostate epithelial cord elongation	GO:0060523	9.48	ESR1 FGFR2
33	positive regulation of MAP kinase activity	GO:0043406	9.46	ERBB2 FGF2 KRAS VEGFA
34	cellular response to hypoxia	GO:0071456	9.35	AKT1 MALAT1 PTEN TP53 VEGFA
35	positive regulation of gene expression	GO:0010628	9.17	AKT1 CDKN2A ERBB2 KRAS PTEN TP53
36	nervous system development	GO:0007399	10.06	AKT1 ERBB2 FGF2 PTEN VEGFA
37	positive regulation of transcription, DNA-templated	GO:0045893	10.02	AKT1 CDKN2A ESR1 ESR2 FGF2 TP53
38	cell proliferation	GO:0008283	10	AKT1 ERBB2 MKI67 PTEN TP53

Molecular functions related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.88	AKT1 CDKN2A ESR1 PTEN TP53
2	identical protein binding	GO:0042802	9.76	AKT1 ERBB2 ESR1 ESR2 PGR PTEN
3	steroid hormone receptor activity	GO:0003707	9.63	ESR1 ESR2 PGR
4	nuclear receptor activity	GO:0004879	9.58	ESR1 ESR2 PGR
5	steroid binding	GO:0005496	9.5	ESR1 ESR2 PGR
6	nitric-oxide synthase regulator activity	GO:0030235	9.49	AKT1 ESR1
7	estrogen receptor activity	GO:0030284	9.43	ESR1 ESR2
8	estrogen response element binding	GO:0034056	9.37	ESR1 ESR2
9	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.26	ERBB2 ESR1 FGF2 FGFR2
10	enzyme binding	GO:0019899	9.17	AKT1 ESR1 ESR2 MLH1 PGR PTEN
11	protein binding	GO:0005515	10.21	AKT1 CDKN2A CTSD ERBB2 ESR1 ESR2

Sources

Sources for Endometrial Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia